Oncotarget

Research Papers:

A single center clinical analysis of children with high-risk neuroblastoma

Xiangdong Tian, Yanna Cao, Jingfu Wang, Jie Yan, Yao Tian, Zhongyuan Li, Huijuan Wang, Xiaofeng Duan, Yan Jin and Qiang Zhao _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:30357-30368. https://doi.org/10.18632/oncotarget.15996

Metrics: PDF 688 views  |   HTML 847 views  |   ?  


Abstract

Xiangdong Tian1,*, Yanna Cao1,*, Jingfu Wang1, Jie Yan1, Yao Tian2, Zhongyuan Li1, Huijuan Wang1, Xiaofeng Duan1, Yan Jin1, Qiang Zhao1

1Department of Pediatric Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of China

2Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of China

*These authors have contributed equally to this work

Correspondence to:

Qiang Zhao, email: qiangzhao169@sina.com

Keywords: neuroblastoma, high-risk, treatment, surgery extent, survival rate

Received: November 16, 2016    Accepted: February 13, 2017    Published: March 07, 2017

ABSTRACT

The current multidisciplinary treatment for patients with high-risk neuroblastoma (NB) is the common census. However, protocols and opinions are different in different regions and institutions. We aimed to assess the protocol formulated by Chinese Children’s Cancer Group study in 2009, and the impact of surgery extent was highlightly evaluated.

Methods: This study enrolled patients with high-risk neuroblastoma between 2009 and 2014 in Department of Pediatric Oncology of Tianjin Medical University Cancer Institute and Hospital. The clinical characteristics of patients were illustrated and surgery extent was evaluated by the impact on survival rate.

Results: The 3-year overall survival (OS) and progression-free survival (PFS) were 56.2% and 50.5%, respectively. LDH (P<0.001), bone marrow metastasis at time of diagnosis (P=0.001), bone marrow negative after neoadjuvant chemotherapy (P<0.001), radiotherapy (P<0.001) were significant predictors of OS and PFS. And surgery extent had no impact on the enhancement of high-risk neuroblastoma patients in short time.

Conclusions: This study showed no substantial survival benefit in patients with high-risk NB undergoing gross total tumor resection. Multidisciplinary intensive treatment was essential, especially for patients received subtotal tumor resection. Longer term follow-up is needed to survey complications in surviving patients who received intensive chemotherapy and radiotherapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15996